Clinical trials recruiting in Wilrijk, Belgium

Phase breakdown

Conditions recruiting in Wilrijk, Belgium

Recruiting trials in Wilrijk, Belgium

• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male
• FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
  NCT07558083 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
  NCT06462963 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female)
• PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
  NCT04790253 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• PrOspEctive Metastases Imaging (POEM)
  NCT07781306 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Preoperative Radiation Therapy and Immediate Breast Reconstruction
  NCT06739655 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma
  NCT06691425 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
  NCT04498767 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• The RECLAIM Study.
  NCT06450444 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 84 Years · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
  NCT05950945 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
  NCT06282588 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male

Common questions

How many clinical trials are recruiting in Wilrijk, Belgium?

22 recruiting trials have at least one study site in Wilrijk, Belgium.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.